{"id":"https://openalex.org/W2476914299","doi":null,"title":"Pharmacoeconomics of cardiovascular disease prevention","display_name":"Pharmacoeconomics of cardiovascular disease prevention","publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2476914299","mag":"2476914299"},"language":"en","primary_location":{"id":"pmh:oai:pure.rug.nl:openaire/2979abd7-00f8-43ea-baf7-e4e77f0794d8","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Stevanovic, J 2015, 'Pharmacoeconomics of cardiovascular disease prevention', Doctor of Philosophy, University of Groningen, [Groningen].","raw_type":"info:eu-repo/semantics/doctoralThesis"},"volume":null,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://research.rug.nl/en/publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003738592","display_name":"Jelena Stevanovi\u0107","orcid":"https://orcid.org/0000-0003-4641-1078","observed_orcids":["https://orcid.org/0000-0003-4641-1078"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Stevanovic, Jelena","raw_affiliation_strings":["Pharmacoepidemiology and Pharmacoeconomics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacoepidemiology and Pharmacoeconomics","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5003738592"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cardiovascular-disease-prevention","display_name":"cardiovascular disease prevention","score":0.9629999995231628},{"id":"https://openalex.org/keywords/pharmacoeconomics","display_name":"pharmacoeconomics","score":0.9459999799728394},{"id":"https://openalex.org/keywords/health-related-quality-of-life","display_name":"health-related quality of life","score":0.8519999980926514},{"id":"https://openalex.org/keywords/evidence-synthesis","display_name":"evidence synthesis","score":0.7829999923706055},{"id":"https://openalex.org/keywords/coronary-artery-disease","display_name":"coronary artery disease","score":0.8479999899864197},{"id":"https://openalex.org/keywords/oral-anticoagulants","display_name":"oral anticoagulants","score":0.8330000042915344},{"id":"https://openalex.org/keywords/vitamin-k-antagonists","display_name":"vitamin K antagonists","score":0.9800000190734863},{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.9900000095367432},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.9919999837875366},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":1.0},{"id":"https://openalex.org/keywords/non-valvular-atrial-fibrillation","display_name":"non-valvular atrial fibrillation","score":0.9269999861717224},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.8999999761581421},{"id":"https://openalex.org/keywords/thromboprophylaxis","display_name":"thromboprophylaxis","score":0.8930000066757202},{"id":"https://openalex.org/keywords/primary-prevention","display_name":"primary prevention","score":0.8569999933242798},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.7850000262260437}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9060218334197998},{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.8715276122093201},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8252661228179932},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.642699658870697},{"id":"https://openalex.org/C2776738588","wikidata":"https://www.wikidata.org/wiki/Q1567856","display_name":"Pharmacoeconomics","level":2,"score":0.590090811252594},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.5311789512634277},{"id":"https://openalex.org/C2777758740","wikidata":"https://www.wikidata.org/wiki/Q2103071","display_name":"Polypill","level":3,"score":0.4455128312110901},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.4303734302520752},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.42826634645462036},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.42101147770881653},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.38845670223236084},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.2803798317909241},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.26352596282958984},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.1387806534767151},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13369959592819214}],"mesh":[],"locations_count":2,"locations":[{"id":"pmh:oai:pure.rug.nl:openaire/2979abd7-00f8-43ea-baf7-e4e77f0794d8","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Stevanovic, J 2015, 'Pharmacoeconomics of cardiovascular disease prevention', Doctor of Philosophy, University of Groningen, [Groningen].","raw_type":"info:eu-repo/semantics/doctoralThesis"},{"id":"pmh:rug:oai:pure.rug.nl:publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/doctoralthesis"}],"best_oa_location":{"id":"pmh:oai:pure.rug.nl:openaire/2979abd7-00f8-43ea-baf7-e4e77f0794d8","doi":null,"is_oa":true,"landing_page_url":"https://research.rug.nl/en/publications/2979abd7-00f8-43ea-baf7-e4e77f0794d8","pdf_url":null,"source":{"id":"https://openalex.org/S4306400420","display_name":"University of Groningen research database (University of Groningen / Centre for Information Technology)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I169381384","host_organization_name":"University of Groningen","host_organization_lineage":["https://openalex.org/I169381384"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Stevanovic, J 2015, 'Pharmacoeconomics of cardiovascular disease prevention', Doctor of Philosophy, University of Groningen, [Groningen].","raw_type":"info:eu-repo/semantics/doctoralThesis"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W71228264","https://openalex.org/W1540777168","https://openalex.org/W1985042952","https://openalex.org/W2000364699","https://openalex.org/W2006546370","https://openalex.org/W2039217072","https://openalex.org/W2042710356","https://openalex.org/W2046186673","https://openalex.org/W2049922379","https://openalex.org/W2073426542","https://openalex.org/W2075655234","https://openalex.org/W2118092611","https://openalex.org/W2130921523","https://openalex.org/W2132419106","https://openalex.org/W2132772102","https://openalex.org/W2134430286","https://openalex.org/W2136411477","https://openalex.org/W2148757932","https://openalex.org/W2170369073","https://openalex.org/W2312193316","https://openalex.org/W2335822722"],"related_works":["https://openalex.org/W2315540858","https://openalex.org/W2253494942","https://openalex.org/W4312046080","https://openalex.org/W4413309436","https://openalex.org/W2151329874","https://openalex.org/W4322774634","https://openalex.org/W4244953505","https://openalex.org/W1661061496","https://openalex.org/W2808162356","https://openalex.org/W1978282910"],"abstract_inverted_index":{"In":[0,139,254],"this":[1,140,259,282,298],"thesis,":[2],"some":[3],"of":[4,33,39,50,60,73,79,112,125,169,221,226,238,290],"the":[5,37,71,76,110,147,167,198,203,212,219,224,278,286,315],"methodological":[6,264],"challenges":[7,26],"in":[8,14,56,84,101,129,197,228,258,274,281,314],"simulating":[9],"and":[10,21,117,133,145,150,177,195,214,232,236,245,266,270,288,293],"synthesizing":[11],"pharmacoeconomic":[12,40,85,156,164,272,291,301],"evidence":[13,74,165,292,302],"cardiovascular":[15],"disease":[16,132],"(CVD)":[17],"prevention":[18,63,188,225,237,276],"were":[19,27,158,247],"assessed":[20],"potential":[22],"solutions":[23],"to":[24,70,108,250,310],"those":[25,115],"proposed.":[28],"This":[29,160],"includes":[30],"a":[31,57,92,307],"set":[32],"recommendations":[34,52,267],"for":[35,185,223,234,268,312],"enhancing":[36],"robustness":[38,72],"analyses":[41],"that":[42,189,242,262,303],"apply":[43],"CVD":[44,62,103,187,275],"risk":[45],"prediction":[46],"models.":[47],"The":[48],"application":[49],"these":[51],"was":[53,89,137,209],"also":[54,162],"explored":[55],"simplified":[58],"model":[59],"primary":[61],"with":[64,207,218,252],"antihypertensives.":[65],"Another":[66],"challenging":[67],"issue":[68],"relates":[69],"on":[75,166],"health-related":[77],"quality":[78,287],"life":[80],"(HRQoL)":[81],"values":[82,100,116,128,149],"used":[83],"analyses.":[86],"Here,":[87],"evidence-synthesis":[88,124],"suggested":[90],"as":[91,105,107],"relevant":[93],"approach":[94],"to,":[95],"where":[96],"appropriate,":[97],"synthesize":[98],"HRQoL":[99,127],"specific":[102],"disorders":[104],"well":[106],"indicate":[109],"level":[111],"heterogeneity":[113,143],"across":[114],"possibly":[118],"its":[119,134],"sources.":[120],"As":[121],"an":[122],"example,":[123],"instrument-specific":[126,148],"coronary":[130],"heart":[131],"underlying":[135],"disease-forms":[136],"explored.":[138,210],"study":[141],"large":[142],"within":[144,155],"between":[146],"inherent":[151],"uncertainty":[152],"if":[153],"applied":[154],"analysis,":[157],"found.":[159],"thesis":[161,260,283,299],"derives":[163],"use":[168,220],"oral":[170,179],"anticoagulants":[171,180],"(i.e.":[172],"vitamin":[173],"K":[174],"antagonists":[175],"(VKAs)":[176],"novel":[178],"(NOACs)":[181],"e.g.":[182],"apixaban,":[183],"dabigatran)":[184],"secondary":[186],"may":[190,284,305],"have":[191],"direct":[192],"societal":[193],"relevance":[194],"implications":[196],"Dutch":[199,316],"setting.":[200,317],"Firstly,":[201],"optimizing":[202],"standard":[204],"anticoagulant":[205],"care":[206],"VKAs":[208,311],"Secondly,":[211],"health":[213],"economic":[215],"consequences":[216],"associated":[217],"apixaban":[222,244],"stroke":[227],"non-valvular":[229],"atrial":[230],"fibrillation,":[231],"dabigatran":[233,246],"treatment":[235,251],"venous":[239],"thromboembolism":[240],"indicated":[241],"both":[243],"favourable":[248],"alternatives":[249],"VKAs.":[253],"conclusion,":[255],"several":[256],"studies":[257,273],"emphasize":[261],"standardizing":[263],"requirements":[265],"conducting":[269],"reporting":[271],"including":[277],"ones":[279],"proposed":[280],"enhance":[285],"validity":[289],"reduce":[294],"possible":[295],"bias.":[296],"Furthermore,":[297],"provides":[300],"NOACs":[304],"present":[306],"valuable":[308],"alternative":[309],"thromboprophylaxis":[313]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-10-04T09:36:47.201465","created_date":"2016-08-23T00:00:00"}